Wang, Rutao
Tomaniak, Mariusz
Takahashi, Kuniaki
Gao, Chao
Kawashima, Hideyuki
Hara, Hironori
Ono, Masafumi
van Klaveren, David
van Geuns, Robert-Jan
Morice, Marie-Claude
Davierwala, Piroze M.
Mack, Michael J.
Witkowski, Adam
Curzen, Nick
Berti, Sergio
Burzotta, Francesco
James, Stefan
Kappetein, Arie Pieter
Head, Stuart J.
Thuijs, Daniel J. F. M.
Mohr, Friedrich W.
Holmes, David R.
Tao, Ling
Onuma, Yoshinobu
Serruys, Patrick W. http://orcid.org/0000-0002-9636-1104
Funding for this research was provided by:
German Foundation of Heart Research
Article History
Received: 2 January 2021
Accepted: 1 March 2021
First Online: 12 March 2021
Declarations
:
: Dr. Serruys reports personal fees from Biosensors, Micel Technologies, Sinomedical Sciences Technology, Philips/Volcano, Xeltis, and HeartFlow, outside the submitted work. Dr. van Geuns reports personal fees from Abbott vascular, grants and personal fees from AstraZeneca, grants and personal fees from Amgen, grants and personal fees from Boston Scientific, personal fees from Sanofi, outside the submitted work. Dr. Morice reports to work as the CEO of CERC, a CRO which was never involved in the SYNTAX trial at any level, except that submitted the 10 years additional follow-up (for free) to French authorities to get approval. Dr. Morice also reports to work as minor shareholder of electroducer. Dr. Burzotta reports speaker’s fees from Abiomed, Abbott and Medtronic. Dr. Kappetein reports to work as an employee of Medtronic, outside the submitted work. Dr. James’s institution has received research grants from Boston Sc, Abbot, Biotronik, Medtronic, Astra Zeneca, Bayer, Jansen, The MedCo, and has received lecture fees from Biotronik, Astra Zeneca. All other authors have no disclosures.